Collectively, our findings highlight MECOM as a therapeutically actionable oncogene in ovarian cancer and demonstrate that small-molecule inhibitors like JIB-04, by epigenetically targeting amplified oncogenes, offer a promising strategy for ovarian cancer treatment. This evidence concerns the gene MECOM and ovarian carcinoma.